If a patient has a dystonic reaction to haloperidol, is the risk equally or worse for recurrence if the medication is attempted to be administered again?

If a patient has a dystonic reaction to haloperidol, is the risk equal or worse for recurrence if the medication is attempted to be administered again?

Comment by InpharmD Researcher

Available literature suggests that a history of medication-induced acute dystonia is a major risk factor for subsequent dystonic reactions, with some data reporting up to a sixfold increased relative risk. However, the risk of recurrence with re-exposure to the same agent, specifically haloperidol, is not defined. One dated investigation (see Table 1) found that prior extrapyramidal symptoms predicted recurrence during subsequent antipsychotic treatment; among patients who developed dystonia during repeat treatment, 72.7% had also experienced dystonia during their initial treatment. Overall, findings suggest that patients with a prior dystonic reaction have an increased risk of recurrence with subsequent dopamine receptor-blocking agent exposure, though the exact magnitude of this risk and the specific risk associated with haloperidol rechallenge remain unclear.

PubMed and tertiary-source searches were conducted using combinations of the terms haloperidol, acute dystonia, dystonic reaction, extrapyramidal symptoms, recurrence, rechallenge, and risk factors. The search identified limited primary evidence directly evaluating recurrence after haloperidol rechallenge; therefore, relevant review articles, consensus guidance, and tertiary sources were included to assess recurrence risk after prior antipsychotic- or dopamine receptor-blocking agent–induced dystonia.

Background

Several review articles suggest that the risk of recurrent acute dystonia is higher in patients with a prior dystonic reaction; however, evidence specifically evaluating recurrence after haloperidol rechallenge is limited. Acute dystonia is a dopamine D2 receptor-blocking agent-induced movement disorder characterized by involuntary muscle contractions that may involve the neck, jaw, eyes (oculogyric crisis), facial muscles, extremities, or other muscle groups. Symptoms typically occur shortly after exposure, with approximately 50% of reactions occurring within 48 hours and 90% within 5 days of initiating therapy or increasing the dose. High-potency antipsychotics, including haloperidol, have a greater risk of causing acute dystonia due to stronger dopamine receptor blockade. Notably, one dated review article notes that a prior acute dystonic reaction is the strongest risk factor for developing another dystonic reaction, with a reported up to six-fold increased relative risk. Additionally, the review cites a prior study in which 30 of 34 patients (88.2%) who developed extrapyramidal symptoms during a second antipsychotic treatment had also experienced extrapyramidal symptoms during their first treatment; when dystonia was evaluated specifically, 8 of 11 patients (72.7%) who developed dystonia during the second treatment had also experienced dystonia during the first treatment (see Table 1). However, this study evaluated antipsychotic-induced extrapyramidal symptoms broadly and was not specific to haloperidol rechallenge. Management recommendations emphasize avoiding the offending medication after an acute dystonic reaction when possible and switching to an alternative agent with lower extrapyramidal symptom risk. If dopamine-blocking therapy is required, anticholinergic therapy (e.g., benztropine) may be considered in high-risk situations; however, long-term prophylactic anticholinergic use is generally not recommended and should be individualized due to potential adverse effects. Overall, the literature supports that a patient with a prior medication-induced dystonic reaction has an increased susceptibility to future dystonic reactions with dopamine receptor-blocking agents, but the exact recurrence risk after re-administration of haloperidol specifically is not established. [1], [2], [3], [4], [5], [6]

Literature Review

A search of the published medical literature revealed 1 study investigating the researchable question:

If a patient has a dystonic reaction to haloperidol, is the risk equal or worse for recurrence if the medication is attempted to be administered again?

Level of evidence

C - Multiple studies with limitations or conflicting results Read more→

Please see Table 1 for your response.

Use of Neuroleptic-Induced Extrapyramidal Symptoms to Predict Future Vulnerability to Side Effects
Design	Retrospective chart review study N= 62
Objective	To determine whether patients’ previous histories of extrapyramidal syndromes predict future episodes of extrapyramidal syndromes and to compare the importance of this predictive factor with patient age, sex, neuroleptic dose, and anticholinergic dose as predictors of extrapyramidal syndromes
Study Groups	All patients (n= 62)
Inclusion Criteria	Patients diagnosed with schizophrenia and medicated with multiple neuroleptic treatments at the facility within 5 years of the index hospitalization
Exclusion Criteria	Patients who had taken oral or depot neuroleptics, anticholinergics, tricyclic antidepressants, or drug overdoses before admission
Methods	Charts were reviewed for age, sex, neuroleptic type and dose, anticholinergic type and dose, and extrapyramidal syndromes during the first 21 treatment days of each hospitalization. Extrapyramidal reactions were recorded only if specifically diagnosed and treated. When patients had more than 2 hospitalizations, the 2 hospitalizations with the most similar neuroleptic drug and dose were selected. Neuroleptic doses were calculated as chlorpromazine equivalents, anticholinergic activities were calculated as benztropine equivalents, and a chlorpromazine-equivalent-to-benztropine-equivalent ratio was calculated. Prior extrapyramidal syndrome history was tested as a predictor of extrapyramidal syndromes during subsequent neuroleptic treatment.
Duration	Not specified
Outcome Measures	Primary: Prediction accuracy of extrapyramidal syndromes based on previous history Secondary: Influence of neuroleptic dose, anticholinergic dose, age, and sex on prediction accuracy
Baseline Characteristics		All patients (n= 62)
	Mean age, years	30.1
	Male	51.6%
	Mean chlorpromazine Equivalents/Day	853
	Mean benztropine Equivalents/Day	0.73
	Ratio of Chlorpromazine Equivalents to Benztropine Equivalents	1168
Results	During the first neuroleptic treatment episode, extrapyramidal syndromes (EPS) occurred in 36 of 62 patients (58.1%), including dystonia in 18 patients (29%), parkinsonism in 18 patients (29%), and akathisia in 13 patients (21%); 14 of 36 patients with EPS (38.9%) experienced more than one syndrome. During the second treatment episode, which occurred a mean of 1.2 years after the first, EPS occurred in 34 of 62 patients (54.8%), including dystonia in 11 patients (17.7%), parkinsonism in 23 patients (37.1%), and akathisia in 17 patients (27.4%); 14 of 34 patients (41.2%) experienced more than one syndrome. Prior EPS history correctly predicted EPS status during subsequent treatment in 52 of 62 patients (83.9%), with a sensitivity of 88.2% and specificity of 78.6%, and was more accurate than a discriminant function excluding prior EPS history, which correctly predicted 42 of 62 cases (67.7%; p<0.001). By EPS subtype, prior dystonia correctly predicted subsequent dystonia status in 49 patients (79.0%), prior parkinsonism correctly predicted subsequent parkinsonism status in 47 patients (75.8%), and prior akathisia correctly predicted subsequent akathisia status in 45 patients (72.6%).
Adverse Events	Not specifically detailed as adverse events, but extrapyramidal syndromes such as dystonia, parkinsonism, and akathisia were observed.
Study Author Conclusions	These results support the hypothesis that patients with a history of extrapyramidal syndromes are at greater risk for future extrapyramidal syndromes. If confirmed, these results strongly support individual susceptibility as a major predictor of extrapyramidal syndromes and indicate that prophylaxis of extrapyramidal syndromes should be considered for patients who have previously suffered extrapyramidal syndromes from similarly prescribed neuroleptic therapy.
Critique	This study is directly relevant to recurrence risk after a prior neuroleptic-induced extrapyramidal syndrome, showing that prior extrapyramidal syndrome history predicted subsequent extrapyramidal syndrome status in 83.9% of patients and was more predictive than a model excluding prior history. However, the study was retrospective, small, limited to patients with schizophrenia receiving neuroleptics, and evaluated extrapyramidal syndromes as a broader category rather than haloperidol-induced dystonia specifically; therefore, it supports increased recurrence vulnerability after prior EPS but does not quantify haloperidol-specific rechallenge risk.

Table 1 References:
[7] Keepers GA, Casey DE. Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry. 1991;148(1):85-89. doi:10.1176/ajp.148.1.85